Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 4/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.35 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177451 | 0.91 | HPGDS (0.38) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL12673076 | 0.91 | NR1H4 (0.40) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL10253815 | 0.86 | HPGDS (0.42) | HPGDSSCN10AMAPK13MAPK12MAPK11 | |
| SCHEMBL9980576 | 0.85 | MAPK13 (0.41) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL1892663 | 0.85 | SCN10A (0.37) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL16511895 | 0.85 | SCN10A (0.44) | HPGDSSCN10A | |
| SCHEMBL18901854 | 0.84 | HPGDS (0.44) | HPGDSSCN10AMAPK13MAPK12MAPK11 | |
| SCHEMBL10253661 | 0.84 | HPGDS (0.44) | HPGDSSCN10AMAPK13MAPK12MAPK11 | |
| SCHEMBL10144865 | 0.84 | HPGDS (0.35) | HPGDSSCN10ANR1H4MAPK13MAPK12 | |
| SCHEMBL15373033 | 0.84 | HPGDS (0.35) | HPGDSSCN10ANR1H4MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | HPGDS 1869/4885SCN10A 4499/4885NR1H4 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.